Catalent Stock Today
| CTLT Stock | USD 61.00 0.25 0.41% |
Performance0 of 100
| Odds Of DistressLess than 35
|
Catalent is selling for under 61.00 as of the 28th of November 2024; that is 0.41 percent increase since the beginning of the trading day. The stock's last reported lowest price was 60.75. Catalent has about a 35 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on March 12, 2019, Representative Susie Lee of US Congress acquired under $15k worth of Catalent's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2014 | Category Healthcare | Classification Health Care |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. The company has 181.51 M outstanding shares of which 9.06 M shares are currently shorted by private and institutional investors with about 4.87 trading days to cover. More on Catalent
Moving against Catalent Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Catalent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | John Chiminski | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP 500 Index, ARCA Pharmaceutical, Drugs, Obamacare Repeal, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCatalent can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Catalent's financial leverage. It provides some insight into what part of Catalent's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalent (CTLT) is traded on New York Stock Exchange in USA. It is located in 14 Schoolhouse Road, Somerset, NJ, United States, 08873 and employs 17,000 people. Catalent is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 11.03 B. Catalent conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 181.51 M outstanding shares of which 9.06 M shares are currently shorted by private and institutional investors with about 4.87 trading days to cover.
Catalent currently holds about 345 M in cash with 268 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.92.
Check Catalent Probability Of Bankruptcy
Ownership AllocationCatalent holds a total of 181.51 Million outstanding shares. The majority of Catalent outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalent to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalent. Please pay attention to any change in the institutional holdings of Catalent as this could imply that something significant has changed or is about to change at the company. On March 12, 2019, Representative Susie Lee of US Congress acquired under $15k worth of Catalent's common stock.
Check Catalent Ownership Details
Catalent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Balyasny Asset Management Llc | 2024-09-30 | 3.6 M | |
| Hhg Plc | 2024-06-30 | 3.1 M | |
| Amvescap Plc. | 2024-06-30 | 2.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.4 M | |
| Eckert Corp | 2024-09-30 | 2.1 M | |
| Deutsche Bank Ag | 2024-06-30 | 2 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 1.9 M | |
| Bank Of America Corp | 2024-06-30 | 1.8 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.8 M | |
| Vanguard Group Inc | 2024-09-30 | 20.2 M | |
| Blackrock Inc | 2024-06-30 | 15.4 M |
Catalent Historical Income Statement
Catalent Stock Against Markets
Catalent Corporate Directors
| Peter Zippelius | Independent Director | Profile | |
| Donald Morel | Independent Director | Profile | |
| John Greisch | Independent Director | Profile | |
| Gregory Lucier | Independent Director | Profile |
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.